SNY vs. MRK
SNY (Sanofi) and MRK (Merck & Co., Inc.) are both stocks. Both operate in the Drug Manufacturers - General industry within the Healthcare sector. Over the past 10 years, SNY returned 4.63%/yr vs 11.28%/yr for MRK. At a 0.41 correlation, their price movements are largely independent.
Performance
SNY vs. MRK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, SNY achieves a -6.78% return, which is significantly lower than MRK's 10.68% return. Over the past 10 years, SNY has underperformed MRK with an annualized return of 4.63%, while MRK has yielded a comparatively higher 11.28% annualized return.
SNY
- 1D
- -0.37%
- 1M
- -1.96%
- YTD
- -6.78%
- 6M
- -9.38%
- 1Y
- -8.16%
- 3Y*
- -1.21%
- 5Y*
- 0.44%
- 10Y*
- 4.63%
MRK
- 1D
- 0.42%
- 1M
- 3.11%
- YTD
- 10.68%
- 6M
- 16.30%
- 1Y
- 57.18%
- 3Y*
- 4.06%
- 5Y*
- 12.86%
- 10Y*
- 11.28%
SNY vs. MRK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
SNY Sanofi | -6.78% | 4.93% | 1.09% | 6.55% | 0.57% | 7.00% | 0.39% | 20.47% | 6.06% | 9.96% |
MRK Merck & Co., Inc. | 10.68% | 9.79% | -6.26% | 1.01% | 49.42% | 1.75% | -7.20% | 22.27% | 39.95% | -1.49% |
Correlation
The correlation between SNY and MRK is 0.43, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.43 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.36 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.36 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.39 |
Correlation (All Time) Calculated using the full available price history since Jul 2, 2002 | 0.41 |
Fundamentals
SNY:
$103.08B
MRK:
$285.89B
SNY:
$3.09
MRK:
$3.58
SNY:
13.86
MRK:
32.26
SNY:
2.21
MRK:
4.40
SNY:
1.42
MRK:
6.23
SNY:
$47.35B
MRK:
$65.59B
SNY:
$34.18B
MRK:
$49.79B
SNY:
$12.63B
MRK:
$22.69B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
SNY vs. MRK — Risk / Return Rank
SNY
MRK
SNY vs. MRK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Sanofi (SNY) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| SNY | MRK | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.33 | 2.14 | -2.46 |
Sortino ratioReturn per unit of downside risk | -0.28 | 3.06 | -3.35 |
Omega ratioGain probability vs. loss probability | 0.96 | 1.37 | -0.40 |
Calmar ratioReturn relative to maximum drawdown | -0.51 | 4.93 | -5.43 |
Martin ratioReturn relative to average drawdown | -1.01 | 12.44 | -13.45 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| SNY | MRK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.33 | 2.14 | -2.46 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.02 | 0.55 | -0.53 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.20 | 0.49 | -0.30 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.20 | 0.48 | -0.28 |
Drawdowns
SNY vs. MRK - Drawdown Comparison
The maximum SNY drawdown since its inception was -46.46%, smaller than the maximum MRK drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for SNY and MRK.
Loading charts...
Drawdown Indicators
| SNY | MRK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -46.46% | -68.61% | +22.15% |
Max Drawdown (1Y)Largest decline over 1 year | -16.70% | -11.37% | -5.33% |
Max Drawdown (3Y)Largest decline over 3 years | -23.37% | -43.44% | +20.07% |
Max Drawdown (5Y)Largest decline over 5 years | -33.52% | -43.44% | +9.92% |
Max Drawdown (10Y)Largest decline over 10 years | -33.52% | -43.44% | +9.92% |
Current DrawdownCurrent decline from peak | -20.60% | -7.74% | -12.86% |
Average DrawdownAverage peak-to-trough decline | -12.19% | -18.85% | +6.66% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.39% | 4.50% | +3.89% |
Volatility
SNY vs. MRK - Volatility Comparison
The current volatility for Sanofi (SNY) is 5.39%, while Merck & Co., Inc. (MRK) has a volatility of 8.19%. This indicates that SNY experiences smaller price fluctuations and is considered to be less risky than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| SNY | MRK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.39% | 8.19% | -2.80% |
Volatility (6M)Calculated over the trailing 6-month period | 14.94% | 17.85% | -2.91% |
Volatility (1Y)Calculated over the trailing 1-year period | 24.93% | 26.92% | -1.99% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 24.68% | 23.64% | +1.04% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.42% | 22.91% | +0.51% |
Dividends
SNY vs. MRK - Dividend Comparison
SNY's dividend yield for the trailing twelve months is around 5.66%, more than MRK's 2.87% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
MRK Merck & Co., Inc. | 2.87% | 3.12% | 3.14% | 2.72% | 2.52% | 3.41% | 3.03% | 2.48% | 2.60% | 3.36% | 3.14% | 3.43% |
SNY Sanofi | 5.66% | 4.56% | 4.22% | 3.83% | 4.32% | 3.80% | 3.61% | 3.47% | 4.29% | 3.82% | 4.11% | 3.77% |
Financials
SNY vs. MRK - Financials Comparison
This section allows you to compare key financial metrics between Sanofi and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
SNY vs. MRK - Profitability Comparison
SNY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Sanofi reported a gross profit of 8.11B and revenue of 11.24B. Therefore, the gross margin over that period was 72.1%.
MRK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported a gross profit of 13.34B and revenue of 16.29B. Therefore, the gross margin over that period was 81.9%.
SNY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Sanofi reported an operating income of 2.27B and revenue of 11.24B, resulting in an operating margin of 20.2%.
MRK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported an operating income of -1.88B and revenue of 16.29B, resulting in an operating margin of -11.6%.
SNY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Sanofi reported a net income of 1.61B and revenue of 11.24B, resulting in a net margin of 14.4%.
MRK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Merck & Co., Inc. reported a net income of -4.24B and revenue of 16.29B, resulting in a net margin of -26.0%.
Frequently Asked Questions
SNY and MRK have a correlation of 0.43, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
MRK has higher volatility (8.19%) compared to SNY (5.39%). In terms of maximum drawdown, SNY dropped -46.46% vs MRK's -68.61%.
MRK currently has the higher Sharpe Ratio (2.14 vs -0.33), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for SNY and MRK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer